
Credit: Isomorphic Labs
2026 is shaping up to be a pivotal year for Isomorphic Labs. In January, it signed Johnson & Johnson as its third pharma partner after Eli Lilly and Novartis, and CEO Demis Hassabis, Ph.D., moved the company’s first clinical trial target to the end of 2026. In May, the Alphabet spinoff raised a $2.1 billion Series B led by Thrive Capital. And now, two days after announcing a $5 billion Series C, the Alphabet-backed AI drug design company signed Merck as its latest partner, agreeing to use selected Merck datasets in its IsoDDE (Isomorphic Labs Drug Design Engine) to design small-molecule candidates against a single oncology target. Isomorphic unveiled IsoDDE in February as a unified computational drug-design system it says goes beyond AlphaFold 3, predicting how strongly a drug binds to its target as well as the structure of the complex.
Isomorphic began working with Lilly and Novartis in January 2024 to find small molecules for multiple targets. Novartis expanded its agreement in February 2025 to add up to three research programs. The Johnson & Johnson deal spans multiple targets and includes small molecules and biologics.
For the oncology project, Isomorphic will run predictions in IsoDDE and deliver molecular designs. By the company’s own benchmarking, IsoDDE more than doubles the accuracy of AlphaFold 3, the structure prediction model Isomorphic developed with Google DeepMind, on the hardest protein-ligand cases in the Runs N’ Poses benchmark.
Merck, which goes by MSD outside the U.S. and Canada, will handle preclinical and clinical development and will manufacture and market any resulting products. “The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” said George Addona, head of discovery, preclinical development and translational medicine at Merck Research Laboratories.
Isomorphic will receive an upfront payment and could earn milestone payments and tiered royalties on net sales. It can also co-fund development in exchange for higher royalties. In the top 20 drugmakers’ 2025 AI drug discovery deals, about 2% of $29.5 billion in headline value was paid up front, McKinsey found.
Isomorphic also plans to use the Series C to advance its internal programs and reported positive preclinical results in oncology and immunology. Isomorphic President Max Jaderberg called those programs “deep in pre-clinical development” on Nov. 2.
Filed Under: Drug Discovery, machine learning and AI, Oncology



